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In view of the ex-plosive nature of the 
advance in immunology in the last decade, 
it is inevitable that immuno'logical tech-
niques would be used in an attempt to 
facilitate the d'iagnosis of cancer. The pur-
pose of this communication is to put into 
perspective the various attempts that have 
been made in this field, and to outline the 
possi:ble outcome of such research. 
The Antigenic Constitution 
of HUman Tumours 
Before discussing ,the posstble use of 
'immunologicall techniques in neopl<astic 
disease it is desi'rable to outline the ways 
in which tumour ceHs differ fwm normal 
cells anti-genically. As seen in Table 1, loss 
of normal tissue antigens can be an im-
portant characteflistic of tumours. Fig. 1 
shows a section of human colon stained 
w'ith an anti-blood group antibody ~anti-H) 
showing that the norma>! human oolonic 
glands have abundant Mood group antigen 
reactivity while the tumour is depleted of 
such antigens. Sim'ilar loss of histocompa-
tibil1ity, orgah specific as well as other nor-
mal antigenicconstituents have been des-
cribed. Fig. 2 shows a section of human 
colon stained with an anti-colon antiserum. 
The normal colon stains brightly, whi'le the 
tumour glands do not. 
In contrast to the loss of antigenic 
oonstituents by tumour ceUs described 
above, <it has been shown in recent years 
that tumours possess antigenic consti-
Fig. 1: Section of human colon carcinoma 
stained with an anti-blood group (anti-H) 
antiserum. Notice that normal glands stain 
brilliantly whH.e tumour tissue (arrow) 
does not. x 210 
tuents that are distinct from nO'rmal adult 
ant'igens. The presence 'Of neoantigens in 
human tumours has now been adequately 
estabE-shed in conditions such as Burkitt's 
lymphoma (Klein et aI., 1967); melanoma 
(Le'wis et aI., 1969), neuroblastoma (Hell-
strom et aI., 1968);osteogeni·c sarcoma 
(Morton and Malgren, 1968); bladder tu-
mours (Bubenik et aI., 1970); Hodgkin's 
disease (Order et aI., 1971) and leukaemia 
(Mathe et aI., 1969). 
In the serum of human foetus one can 
portant recent results on the identification 
and practical applica1Ji.on of 'immune res-
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ponses to the diagnosis of human tumours 
will be delineated. 
Table 1 
Antigenic Changes in Tumours 
1. Loss of Normal Antigens, e.g. 
a. blood group antigen 
b. organ specific antigen 
c. histocompatibility ant'igen. 
2. Reversion to Foetal Type Antigenic 
Constitution, e.g. 
a. Ca'rcinoembryon:'c antigen 
h. a-foetoprotein production 
c. metaplasia-asSGoiated antigen. 
3. Gain of Tumour Specific Antigens 
a. individual speoific antigens, e.g. 
carcinogen induced. 
b. group antigen (cross-reacting) 
e.g. viral induced tumours, Bur-
kitt's lymphoma, melanomas, car-
cinoma of the colon, etc. 
a-Foetoprotein and Hepatoma 
In the following pages the more im-
detect by gel diffusion and immunoelectro-
phores:s techniques a globulin which mig-
:rates in the a! regi'on (Fig. 3). Such a glo-
bulin 'is not detected in normal adult sera. 
In 1964 Tatarinov repmted the presence 
of this foetoprotein in the sera of patients 
with prima'ry hepatoma. Fig. 4 shows the 
gel diffusion pattern O'f foeta.J serum and 
serum from patients with hepatoma. This 
is a simple test for hepatoma, beilllg posi-
tive in 50-80% of patients who have it. 
This test is being used at the moment in 
a WHO survey of the incidence of hepa-
toma in Af'rioa (Muir, C.S., pe.rsonal com-
munication). The recent demonstration of 
minute amounts of foetoprotein by radio-
immunoassay techniques in normal adult 
sera (Rouslaht'i and Seppala, 1971) does 
not detr.act from the practica.l usefulness 
of this test in olinkal practice. 
The significance of a foetO'protein re-
emerging in the adult circulation is a very 
intriguing one. Using tlssue culture tech-
n'iques Gitlin and Boesman (1967) have 
shown tha t the protein can be produced 
by foetal liver cells. We have localised 
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Fig. 2: Sectio.n o.f human co.Io.n carcino.ma 
stained with a ,specific anti-co.Io.n antise-
rum to. sho.W absence o.f staining in the 
tumo.ur glands (B) co.mpared Ito. no.rmal 
(A), indicating 1o.SS of o.rgan-specific anti-
g·ens. x 210 
a-foetoprotein in human foetal Ever ceHs 
and hepatoma using indirect immunofluor-
escent techniques (Cauchi and Nairn, 
1972a). Briefly, fresh tissues were snap 
frozen in a liquid nitrogen-'isopentane mix-
ture and 6fL thick sections were cut, stadn-
ed with a spedfic rabbit anti-a-foetopro-
tein, washed and a fluoresce in-conjugated 
goat-anti-rabbit globulin was added. Using 
this technique, the presence of cells which 
are capable of b'inding with an anti-a-foe-
toprotein anti--serum, (and hence presum-
ably containing a-foetoprotein) could be 
demonstrated in both foetal liver (Fig. 5) 
as well as in sections from a hepatoma, 
but not in norma,l .tissues. 
Fig. 3: Immuno.electro.pho.resis lo.f human 
fo.etal serum reacted with an antifo.eto.pro.-
tein antiserum: a-foeto.pro.tein migrates in 
the a 1 glo.bulin regio.n 
Testing for a-foetoprotein has now 
become a routine test in a la·rge number of 
hospital laboratories and has proven ,to be 
the most s-imple spec'ific test for human 
hepatoma. The test is indicated in patients 
with: 
a. a hepatic mass of unknown aetio-
logy, 
b. drrhosis or chronic liver disease 
of any type, 
~. presumed "metastatic" cancer 
where a primary tumour cannot 
be detected (Stillman and Zam-
check, 1970). 
Carcinoembryonic Antigen (CEA) 
and Gastrointestinal Cancer 
In 1965, GoldC1.nd Freedman obtained 
an extract f,rom carcinoma of the colon 
and succeeded 'in ,immunizing rabbits to 
produce an antibody which reacted s~e­
cifically with colonic cancer but not wIth 
normal tissue. Later on this antigen was 
also found in other tumours of entoder-
mal origin, e.g. oesophagus, stomach, pan-
creas, as well as in metastases of such tu-
mours in the liver. As this antigen was 
shown also to be present ,in the normal 
gastrointestina'l tract of human foetuses of 
2-6 months gestation, this antigen was 
caned ca'rcinoembryonic antigen (CEA). 
The real impetus to the clinical appli-
cation of this knowledge came with the 
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Fig. 4: Gel diffusion show-
ing immunological reaction 
between a specific anti-foe-
tal serum (centre well) and 
human fn~tal serum (wells 
3 and 6), amniotic fluid 
(well 4), and serum from a 
patient with hepatoma 
(well 5). There is no re-
action with normal adult 
serum (well 2). 
discovery that CEA is present in detect-
able concentrations in the sera of pafients 
with cancer of the gastrointestinal tract. 
US'ing a sensitive radioimmunoassay tech-
nique capable of detectrng 2.5ng of 
CEA/ml (1 ng = 10-9 gm) Gold and his 
associates (Thompson et al., 1969) have 
shown that the level of CEA can be higher 
than 300 ng/ml in some patients with car-
cinoma of the colon. 97% of patients with 
cardnoma of the colon had signIficantly 
higher than normal levels of CEA in the 
serum. 
Since these original discoveries a 
number of tumour immunologists have 
been engaged in the production of a simple 
and reliable immunoassay test for the de-
tection of carc'inoma of the colon. At the 
moment we are in the process of provid-
ing a simple radiometrk test that can be 
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Fig. 5: Frozen section of fo.etal human Jiver 
stained with anti-foetal serum showing 
fluorescence of hepatic cells x 210 
applied to the detecNon of CEA (Reid and 
eau chi, 1972). 
The presence of antibody specific to 
CEA in the serum of some patients with 
carcinoma of the colon has been described 
(Gold, 1967) but data on this top'ic are 
conflicting (La Gerfo et al., 1972). It is con-
ceivab!e that a large tumour mass can act 
as an antigenic "sink" abso'rbing an serum 
.antibody activity. It is more likely, how-
ever, that the host is in some way incap-
able' of responding to the large pa'ralysing 
dose of circulating antigen, giving r,ise to 
a situation analogous to "immunologica'l 
paralysis" (Mitchison, 1964). It is unNkely 
that the host is tnherently incapable of 
responding to foetal-type antigen if these 
were presented in a suitable manner, since 
we have shown that a host can produce 
speci'£ic ant'i-foetal antibody activity when 
immunized w~th foetal tissues (Cauchi and 
Nairn, 1972b). Fig. 6 shows a foetal intes-
tinal cell stained by a specific isologous 
anHfoetal intestine antiserum, showing 
the typical membrane sta'ining. As iNus-
trated in thrs figure, CEA is largely a sur-
face bound antigen. 
Other "Embryonic" type Antigens 
Associated with Neoplastic Disease 
Table 2 summa'rises the data on the 
various antige·nic systems described ,in 
human tumours relating to embryonic type 
antigens. The p,lacental alkaline phospha-
tase (Regan isoenzyme) is found in the 
sera of 4-5% of patients w'jlth various ma-
Hgnanc:es. Stohlbach et al. (1969) found 
an alkaline phosphatase i:soenzyme in the 
serum of a patient (Rega,n by name) but 
not in norma'l adult tissues. It is chemically 
and immunologicaHy indistitnguishable 
from placental aIkaline phosphatase. It 
appears to be produced by the tumour 
itself. The heteroph'jlle foetal antigen des-
cr~bed by Edynak et al. (1970) qS non-
species-spedfic and seems to be present in 
a large variety of tumours, benign or ma-
lignant. To date these tests have not found 
widespread cEnica'l application, but might 
be useful eventually as non-specific tests 
for the detection of cance!!". 
Metaplasia-associated Antigen 
It has been shown that intestinal meta-
rpIasia which occurs in gastric tumours in 
man (Mi'ng et aI., 1967) and ,animals (Feit 
et aI., 1967) may be associated with the 
loss of adult-specific antigens and the re-
emergence of an intestinal-type antigen 
(de Boer et aI., 1969; de Boer and Cauohi, 
1971). This can be shown quite re.adi'ly in 
the experimental animal following suoh 
carcinogenic agents as X-'jrradiation. Such 
a distribution of intestinaI antigen in the 
stomach is incidentally the norma,l finding 
in the foetus (de Boer et al., 1969), indicat-
ing that this anti:genic change can be con-
side·red as a revelrS'ion to a foetal antigenic 
distribution. Fig. 7 shows a frozen section 
of human carcinoma stained wIth an anti-
serum to show intestinal-type antigen. 
The search for antigenc constituents 
in gastro'ntestina1 secretions wh'ioh are 
specific for cancer appears attractive. Hak-
kinen and Viikari (1969) reported a new 
test for th~ diagnosis of gast-ri'c cancer 
based on the de,tection of a sulphoglyco-
protein in the gastric juice of patients with 
gastric cancer. This test was positive in 
96% of patients with gastric cancer com-
pared to 9.4% of "control" patients. The 
re~atively high incidence of fa1se posit'ive 
tests in conditions like benign peptic ulcer 
(14%) lim;ts the usefulness of such a test 
unHl it can be demonstrated that the test 
can be made more specific for gastric neo-
plasm. 
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Tumour Antigens 
in Lymphoma and Leukaemia 
In 1964, Epstein et al., found intra-
cellular DNA virus, nO'W known as the 
Epstein Harr Virus (EBV) in cultured cells 
from a patient with Burkitt's lymphoma. 
Antibodies to EBV were rfound in a large 
proportion of normal peopile te'Sted, and 
their distribution is world wide. However, 
high levels of anti-EBV antibody titres 
(more than 1:160) have been found only 
in three conditions Vliz: infectious mono-
nucleosis, Burkitt's lymphoma and naso-
p'haryngeal carc:noma (Henle and Henle, 
1969). Kllein et aI., (1966) using indirect 
immunofluorescent techniques demonstrat-
ed 7S immunoglobulins in the sera of pa-
tients with Burkitt's lymphoma that reacted 
with surface antigens of Jymphoma cells, 
but not of normal cells. Other antibodies 
reacting with cytoplasmic constituents of 
Table 2 
Embryonic-Type Antigenic Constituents in Human Tumours 
Antigen 
a'-foetoprotein 
Cardnoembryonic 
(C-EA) 
Foetal Sulphoglyco-
protein 
Tumour glycolipids 
T-globulin 
Regan isoenzyme 
a,-ferroprotein 
Heterophile foetal 
Antigen 
Cancer 
Hepatoma, teratoma 
GIT cancer 
Gastric cancer 
GIT cancer 
Various cancers 
D:gestive tract and 
various malignant 
tumours 
Localisation 
serum, tumour 
ceH membrane 
(glycooaHx) 
serum 
gastric juice 
tumour 
serum 
tumour ceHs 
Ma'lignant tumours of serum 
childhood (nephro-
blastoma, neuroblast-
oma, teratoma, etc.) 
Various tumours serum 
Ref. 
Abelev et al. 1967 
Gold and Freed-
man 1965 
Hakkinen 1966 
Rapport et al. 
1959 
Tal et al. 1970 
Stolbach et al. 
1969 
Buffe et al. 1970 
Edynak et al. 
1970 
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Fig. 6: A foetal intestinal cell stained by 
an anti-foetal serum to illustrate cell mem-
brane immunofluorescence x 540 
lymphoma cells have been descr,ibed by 
Henle et al., (1969). The fo'Howing antigens 
have now been described in Burkitt's lym-
phoma ceHs (CHfford, 1972). 
" 1. Early antigen (EA): a soluble anti-
gen~ which appears intracellularly 
sooIi after infec1lion with EBV. 
2. Membrane antigen complex (MA): 
on the surface of Burkitt's lympho-
ma cells, probably representing viral 
envelope constituents. 
3. Viral capsid antigen (VCA): a "late" 
viral product present 'in the cyto-
plasma of Burkitt's 'lymphoma cells. 
Although such antigenic systems have 
not been used [or the diagnosis of Bur-
kitt's lymphoma, further studies might in-
dicate that changes 'in the levels of anti-
body might be related to prognosis foNow-
ing surgery, chemotherapy etc. For exam-
ple, the highest levels of anti-VCA titres 
were found in patients with large tumours, 
while low levels were found in patients 
with long term remisSlion. On the other 
hand, high anti-MA titres correlated bet-
ter w'lth a small tumour mass, indicating 
absorption of the antibody by the tumour 
mass (Henle et' al., 1969). A rise in anti-MA 
ant:body titres usuaHy occurs in patients 
who respond weE to ohemotherapy or Iocal 
irradiation {Einhorn e't al., 1970). 
During the last few years we have 
been working on the antigenic constitu-
tion O>f leukaem'ic cells and their ability 
to stimulate an immune response in the 
patient. There is IitNe doubt now that 
leukaemia-specific antigens do exist (Viza 
ec al., 1969) and that the patient can res-
pond to such antigens by the production 
ot antibodies or a cell-mediated immune 
response (Powles et al., 1971). More work 
'is, however, required before these data 
can be of prognostic vaIue. In particular 
with the more widespread use of immuno-
therapeutic techniques, the accurate mea-
surement of the immune status will be an 
essential parameter in detecting host res-
ponse. That such a response is necessarily 
complex, time - as weH as dose - relat-
ed has been shown extensively in experi-
menta'l systems (Cauchi, 1972). 
Immunologic Detection 
of Tumour Secretions 
Certa'in tumours secrete substances or 
hormones which can be detected by sen-
sitive immunological techniques. For ex-
ample, radioimmunoassay teohniques have 
been used to measure chorionic gonado-
trophin from chorionepithel,iomas, calci-
tonin from thyroid carcinoma, gastr'in ,from 
pan~reatic tumours 'producing the ZoHin-
ger Ellison syndrome, insulin from pan-
creatic tumours, and ACTH ,from Piituitary 
and lung tumours (WHO, 1972). These 
methods may eventua'lly become useful in 
Fig. 7: Section of irradiated stomach 
stained with an anti-colon antiserum to 
show the presence of intestinal-type anti-
gens x 340 
the diagnosis of hormone-secreting tu-
mours. 
Macrophage Slowing Factor (MSF) 
in Cancer 
It has been shown recently that blood 
lymphocytes from patients with neoplas-
tic disease were sensitized to an antigen 
which could be extracted from normaI 
brain (Field and Caspary, 1970), or from 
a var1iety of malignant tumours (Caspary 
and Field, 1971). Following inter.action of 
lymphocytes with the anfigen, a factor is 
released which slows the migration of 
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macrophages by about 14-20% of normal. 
This is a re'l'atively simple test which might 
eventuaHy be useful as a non-specific test 
for cancer. 
Autoantibodies in Neoplastic Disease 
It is very difficult to 'interpret the sig-
nificance of .autoantibodies to normal tis-
sue constituents in patients with neoplas-
tic disease. Firstly some forms Df neoplas-
tic disease have a greater tendency to 
occur in patients with specific autorimmune 
diseases. For example carcinoma of the 
cDlon is about 20 times more common in 
patients with ulcerative coHfis than in the 
general population. Secondly, tumours and 
autoimmune disease process might be as-
sooiated in some ill defined way, e.g. the 
presence of thymoma and myasthenia gra-
vis. Thirdly, there is the well known asso-
ciation between .auto immune haemolytic 
anaem'ia and conditions like Hodgk,in's dis-
ease, lymphatic leukaemia and more re-
cently o1:her tumours, e.g. ovarian dermoid 
cyst (Baker et al., 1968). Fourthly, and per-
haps more specificaHy, tumours might sti-
mulate the production of antibodies that 
cross react with normal constituents. The 
finding of a smooth muscle antibody in 
67.5% of patients with mal'ignant disease 
(Wh'itehouse and Holborow, 1971) faUs in 
this category. This work needs confirma-
tion. We have not been able to confirm 
such findings (Tannenberg et' al., 1972). 
The destructrion of a large mass of 
tissue by irradiation, chemotherapy etc., 
might itself produce sufficient stimulus for 
the production of autoantibodies. Antibody 
formation aga,inst skin (Qu'ismorio, et al., 
1971), ileucocytes Wrice et al., 1969), nuclei 
(Weir, 1966), etc. have been shown to' 
occur after tissue necrosis following heat, 
r.adiotherapy, or infarction. 
Although interesting biologicalJ:ly, such 
auto immune phenomena are unlikely to be 
of practical value 'in the diagnos,is of can-
cer. 
Conclusions 
One can envisage a number of ways 
in which immunologic tests for cancer can 
be useful in future dinical practice. 
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,a. In the diagnosis of tumours prior 
to surgical biopsy. So far this is a routine 
test only in the case of hepatocellular car-
cinoma. 
b. In the detection of recurrence 
after surgical removal of a primary carci-
noma. This has obvIous application ,in gas-
tro:ntestinal teact cancer, hepatoma, etc. 
c. In screening programmes for the 
detection of cancer where there ,is an ende-
mica.I1y high incidence, e.g. hepatoma, Bur-
k:tt's ~ymphoma 'in A:frica. 
d. In determining the prognosis of 
tumour patients. It has been shown that 
antibody titres vary according to tumour 
mass, the presence of metastasis etc. This 
may be co:related with ultimate prognos,is. 
e. Using radioactively labeHed high-
ly specific antitumour anfibodies, the 
10caHsation of tumour metastasis, 'involved 
lymph nodes, etc. would provide a rapid 
objective assessment of tumour spread. 
f. As an objective test in the control 
of tumours by immunotherapy. 
In painting an optimistic future for 
the role of tumour immunology in cl'inical 
practice one must not forget that a great 
dea-l of fundamenta,l work is sUlI required 
to delineate the exact biological signific-
ance of tumour-specific antigens. Such 
work at the moment is being carried out 
in major tumour immunO'logy centres 
throughout the world, and one would hope 
that the next ten years wi:ll witness the 
same rate of growth in the application of 
immuno!ogica.I techniques to the cancer 
problem that has been characteristic of 
basic immunologica,l research ,in the last 
decade. 
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LUMBAR SYMPATHECTOMY IN THE TREATMENT 
OF INTERMITTENT CLAUD'ICATION: 
AN OBJECTIVE STUDY 
L. CUTAJAR 
M.D., F.R.C.S.(Eng.), F.R.C.S.(Edin.l 
Summary 
Sympathectomy in twenty legs suffer-
ing from atherosclerotic peripheral vascu-
lar disease made no improvement in the 
muscle blood flow as detected objectively 
by the Technetium (99mTc) Clearance 
Technique in nineteen of these legs. It is 
postulated that intermittent claudicaion 
per se is not an indication for sympathec-
tomy although the operation may have a 
place in the treatment of early nutritional 
disturbances in the ischaemic leg. 
It is still a fairly widespread practice 
to submit patients who present with the 
symptoms of intermittent claudication to 
the operation of lumbar sympathectomy. 
It is the impression of some surgeons that 
many of these cases aoquire worthwihHe 
improvement in their symptoms. However, 
there is no objective evidence to support 
this view and indeed there is experimental 
evidence (Myers and Irvine, 1966a) that 
the operation should not be expected to 
allay the pain of inte,rmittent claudication. 
The object of this paper is to present 
the results of an objective study on a 
s8!1ies of patients, a1U complaining of inter-
mittent claudication (some also with rest 
pain and/or trophic skin changes) who 
were assessed both clinically and object-
ively uS'ing a radio-active tracer technique 
before and after they had undergone 
lumbar sympathectomy. 
Material 
Fifteen patients, all with occlusive 
peripheral arterial di,sease proved by 
arteriography, were studied. Five patients 
had symptoms in both legs so that, in all, 
this ser·ies comprises twenty limbs. All 
patients complained of intermittent clau-
dication in one or both limbs, four patients 
(six legs) had rest pain while marked 
ischaemic (trophic) changes were present 
in ten legs. 
Method 
All legs were studied by recording 
muscle blood flow in the lateral gastroc-
nemius at rest and during exercise. The 
technique has been described elsewhere 
(Cutajar et al. 1971). 
